Cancer Research Institute Elevates Next Generation of Scientists with Significant Investment in Immunotherapy Fellowships
admin The Cancer Research Institute (CRI) has announced the recipients of its Fall 2025 and Spring...
biotech
Dr. Aaron Whiteley Awarded Cancer Research Institute STAR Grant for Pioneering Work in Ancient Immune Pathways and Immunotherapy
The Cancer Research Institute (CRI) has recognized Dr. Aaron Whiteley, an Assistant Professor in the...
Moderna’s Individualized mRNA Cancer Vaccine Demonstrates Significant Efficacy in Interim Trial Data, Bolstering Shares and Oncology Hopes
An interim analysis of a pivotal clinical trial for Moderna’s individualized mRNA cancer treatment, intismeran...
Biopharma Sector Buzzes with Activist Demands, AI Partnerships, and Novel Therapeutic Advancements
The biopharmaceutical landscape is currently experiencing a dynamic period, marked by significant strategic maneuvers from...
The Battle for the Billion-Dollar Weight Loss Market: Eli Lilly and Novo Nordisk Navigate Innovation, Affordability, and Perception
The pharmaceutical titans Eli Lilly and Novo Nordisk are locked in an intense, high-stakes competition...
Ultragenyx, after setbacks, nabs first gene therapy approval
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Genglycos, Ultragenyx Pharmaceutical...
Moderna’s Intismeran Achieves Landmark Phase 3 Success in Melanoma, Igniting a Historic Stock Surge and Revitalizing Personalized Cancer Vaccine Hopes
After a challenging period that saw its stock price plummet from pandemic-era highs, Moderna, in...
Regeneron to challenge Ipsen as FDA clears bone disease drug
The U.S. Food and Drug Administration (FDA) has granted approval to Regeneron Pharmaceuticals’ Pasatru (garetosmab),...
August’s Make-A-Will Month Underscores Critical Role of Legacy Gifts in Advancing Cancer Research Institute’s Quest for a World Immune to Cancer.
The Cancer Research Institute (CRI), a global leader in advancing immunotherapy, is highlighting the profound...
Amylyx’s bet on a GLP-1 blocker pays off
Boston-area biopharmaceutical company Amylyx Pharmaceuticals has reported overwhelmingly positive results from a pivotal Phase 3...
